[en] BACKGROUND: Platelet count and function are particularly damaged by cardiopulmonary bypass (CPB). This study evaluated the effects of a novel CPB circuit in terms of platelet count and activation, and postoperative need for blood products. METHODS: One hundred patients undergoing coronary grafting were randomized in two groups: control group (n = 50) and test group (n = 50, surface modifying additives circuit, SMA group). Blood samples were taken before, during, and after CPB. Postoperative blood loss, number of transfused blood products, and postoperative variables were recorded. RESULTS: The platelet count decreased less in the SMA group compared to the control group (end of CPB: respectively, 165 +/- 9 x 10(3)/mm3 vs 137 +/- 8 x 10(3)/mm3; p < 0.01). This was paralleled by a reduction in beta-thromboglobulin plasma levels in the SMA group. There was a trend to decreased blood loss in the SMA group, but the difference was significant only in patients taking aspirin preoperatively (p < 0.05). In the SMA group nearly 50% less fresh frozen plasma and platelet units were administered (p < 0.01). No operative deaths were observed. CONCLUSIONS: The use of circuits with surface additives is clinically safe, preserves platelet levels, and attenuates platelet activation. This may lead to a reduced need for blood products.
Disciplines :
Surgery
Author, co-author :
Defraigne, Jean-Olivier ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie générale
Pincemail, Joël ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie cardio-vasculaire
Dekoster, Guy ; Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique
Larbuisson, Robert ; Centre Hospitalier Universitaire de Liège - CHU > Anesthésie et réanimation
Dujardin, Marc ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé au travail et éducation pour la santé (STES)
Blaffart, Francine ; Centre Hospitalier Universitaire de Liège - CHU > Bloc opératoire chirurgie cardio-vasculaire
David, Jean-Louis ; Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)
Limet, Raymond ; Université de Liège - ULiège > Département des sciences cliniques > Chirurgie cardio-vasculaire et thoracique
Language :
English
Title :
Sma Circuits Reduce Platelet Consumption and Platelet Factor Release During Cardiac Surgery
Van Oeveren W., Kazachtchkine M.D., Descamps-Latscha B. (1985) Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 89:888-899.
Lovinger A.J., Han B.J., Padden F.J., Mirau P.A. (1993) Morphology and properties of polycaprolactone-poly(dimethylsiloxane)-polycaprolactone triblock copolymers. J Polymer Sci 31:115-123.
Jessen M., Li J., Harris F. (1996) Platelet and neutrophil distribution in pump-oxygenator circuits I. Influence of "SMA" surface treatment. ASAIO J 25:21-26.
Gu Y.J., Boonstra P.W., Rijnsburger A.A., Haan J., Van Oeveren W. (1998) Cardiopulmonary bypass circuit treated with surface modifying additives: A clinical evaluation of blood biocompatibility. Ann Thorac Surg 65:1342-1347.
Harker L., Malpass T.W., Branson H.E., Hessel II E.A., Slichter S.A. (1980) Mechanisms of abnormal bleeding in patients undergoing cardiopulmonary bypass. Acquired transient platelet dysfunction associated with selective α-granule release. Blood 56:824-830.
George J.N., Pickett E.B., Saucerman S. (1986) Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 78:340-344.
Kestin A.S., Khuri S.F., Loscalzo J. (1993) The platelet function defect of cardiopulmonary bypass. Blood 82:107-117.
Khuri S.F., Valeri R., Losacalzo J. (1995) Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 60:1008-1014.
Dechavanne M., French M., Pages J. (1987) Significant reduction in the binding of a monoclonal antibody (LYP 18) directed against the IIb/IIIa glycoprotein complex to platelets of patients having undergone extracorporeal circulation. Thromb Haemost 57:106-111.
Walz D.A. (1984) Platelet-released proteins as molecular markers for the activation process. Semin Thromb Hemost 52:236-239.
Mezzano D., Aranda E., Urzua J. (1986) Changes in platelet β-thromboglobulin, fibrinogen, albumin, 5-hydroxytryptamine, ATP, and ADP during and after surgery with extracorporeal circulation in man. Am J Hematol 22:133-137.
Colman R.W. (1990) Platelet and neutrophil activation in cardiopulmonary bypass. Ann Thorac Surg 49:32-34.
Wachtfogel Y.T., Musial J., Jenkin B., Niewarowski S., Edmunds L.H., Colman R.W. (1985) Loss of platelet α2-adrenergic receptors during simulated extracorporeal circulation: Prevention with prostaglandin. J Lab Clin Med 105:601-605.
Aren C., Feddersen K., Radegran K. (1983) Effects of prostacyclin infusion on platelet activation and postoperative blood loss in coronary bypass. Ann Thorac Surg 36:49-54.
Westaby S. (1993) Aprotinin in perspective. Ann Thorac Surg 55:1033-1041.
Bidstrup B.P., Harrison J., Royston R. (1993) Aprotinin therapy in cardiac operations: A report of use in 41 centres in the United Kingdom. Ann Thorac Surg 55:971-976.
Czer L.S.C., Bateman T.M., Gray R.J. (1987) Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass. Reduction in blood product usage with desmopressin. J Am Coll Cardiol 9:1139-1144.
Muehrcke D.D., McCarthy P.M., Kottke-Marchant K. (1996) Biocompatibility of heparin-coated extracorporeal bypass circuits: A randomized, masked clinical trial. J Thorac Cardiovasc Surg 112:472-483.
Defraigne J.-O., Pincemail J., Larbuisson R., Blaffart F., Limet R. (2000) Cytokines release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann Thorac Surg 69:1092-1097.
Farrar D.J., Litwak P., Lawson J.H. (1988) In vivo evaluations of a new thromboresistant polyurethane. J Thorac Cardiovasc Surg 95:191-200.
Rubens F.D., Labow R.S., Lavallee G.R. (1999) Hematologic evaluation of cardiopulmonary bypass circuits prepared with a novel block copolymer. Ann Thorac Surg 67:689-696.
Simon T.L., Akl B.F., Murphy W.P. (1984) Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg 37:359-364.
Murkin J.M., Lux J., Shannon N.A. (1994) Aprotinin decreases significantly bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 107:554-561.
